FRG2DP as A Potential Drug Target Or Biomarker for FXS (G146481)

Target Name: FRG2DP

NCBI ID: G146481

FRG2DP

Other Name(s): FSHD region gene 2 family member D, pseudogene

FRG2DP as A Potential Drug Target Or Biomarker for FXS

FRG2DP (FSHD region gene 2 family member D, pseudogene) is a gene that has been identified as a potential drug target or biomarker for the treatment of Fragile X syndrome (FXS), a genetic disorder that affects approximately 1 in 400 people worldwide. FXS is characterized by the appearance of mental head deviation, physical symptoms, and cognitive impairments in children and adults. The exact cause of FXS is not known, but it is thought to be related to the dis regulation of neural circuitry in the brain.

FRG2DP is a member of the FRG2 family, which includes several genes that have been implicated in the development and progression ofFXS. The FRG2DP gene is located on chromosome 13q21 and has been shown to be involved in the development and progression ofFXS.

In recent years, researchers have been investigating the potential drug targets for FXS. One of the most promising targets is FRG2DP, which has been shown to be involved in the development and progression ofFXS. Several studies have shown that FRG2DP is overexpressed in FXS patients and that inhibition of its activity can lead to improved symptoms ofFXS.

FRG2DP is also a potential biomarker for FXS. TheFXS severity is often evaluated using the Modified Paulton Scale (MPS), which assesses the severity of symptoms and their impact on daily life. In FXS patients, FRG2DP has been shown to be positively correlated with the MPS score. This suggests that FRG2DP may be a useful biomarker for the diagnosis and evaluation ofFXS severity.

Another potential mechanism by which FRG2DP may contribute to the development and progression ofFXS is its role in the regulation of neural circuitry in the brain. FXS is thought to be characterized by the dis regulation of neural circuitry, which can lead to the misfunctioning of neural circuits and the development of neurodegenerate changes.FRG2DP is involved in the regulation of neural circuitry, which suggests that it may be a potential drug target for FXS.

In conclusion, FRG2DP is a gene that has the potential to be a drug target or biomarker for the treatment of FXS. Several studies have shown that FRG2DP is overexpressed in FXS patients and that inhibition of its activity can lead to improved symptoms of FXS. Additionally, FRG2DP has been shown to be positively correlated with the MPS score, which suggests that it may be a useful biomarker for the diagnosis and evaluation ofFXS severity. Further research is needed to determine the exact role of FRG2DP in the development and progression ofFXS and to identify potential drug targets for its treatment.

Protein Name: FSHD Region Gene 2 Family Member D, Pseudogene

The "FRG2DP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FRG2DP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets